“`html
Travere Therapeutics (NasdaqGM:TVTX) has seen its average one-year price target revised to $42.33 per share, reflecting a 16.27% increase from the previous estimate of $36.41 made on November 7, 2025. This new target indicates a potential upside of 22.70% from the latest closing price of $34.50 per share.
As of the latest report, 485 funds or institutions are holding positions in Travere, an increase of 32 or 7.06% from the last quarter. Total shares owned by institutions rose by 1.94% to 122,018K shares. The put/call ratio stands at 0.65, suggesting a bullish outlook among investors.
Notable shareholders include Janus Henderson Group with 10,600K shares (11.85% ownership) and an increase of 9.99% in recent filings, despite a 35.61% decrease in portfolio allocation. Other significant shareholders such as Armistice Capital and Perceptive Advisors have also adjusted their holdings in the company.
“`
